22 09, 2026

New evidence on variability of plasma miR-122 published with contribution of TAmiRNA

2026-09-22T10:58:24+02:00September 22nd, 2026|biomarker, circulating miRNAs, DILI, drug-induced liver injury, microRNA services, miND, miND spike ins, RNA, small RNA-sequencing, smallRNA, TransBioLine|Comments Off on New evidence on variability of plasma miR-122 published with contribution of TAmiRNA

A short communication published in the British Journal of Clinical Pharmacology re-evaluates the inter- and intra-individual variability of circulating miR-122 in healthy volunteers, using small RNA sequencing generated on TAmiRNA's miND workflow (Javid et al., 2026, doi:10.1002/bcp.70836). Background MicroRNA-122 (miR-122) is a liver-enriched circulating microRNA and one of the most extensively studied candidate biomarkers for drug-induced liver injury (DILI). A 2019 evaluation by Church et al. reported substantial inter- and intra-individual variability of miR-122 in healthy volunteers, which raised questions about its use as a diagnostic biomarker. The present study, conducted within the IMI2 TransBioLine consortium, set out to re-examine this variability in new, independent cohorts. Study and findings Plasma samples from 280 healthy volunteers were collected [...]

8 09, 2026

TAmiRNA Joins Six European RNA Specialists to Launch the European RNA Alliance

2026-09-10T10:01:04+02:00September 8th, 2026|biomarker, circulating miRNAs, ERA, European RNA Alliance, EV characterization, exosomes, extracellular vesicle, microRNA services, miND, miND spike ins, RNA, small RNA-sequencing, smallRNA|1 Comment

As a founding member of ERA, TAmiRNA positions itself as the innovative driving force behind RNA biomarker development in Europe — combining novel biomarker products with premier research services in cell-free RNA and EV/exosome analysis. Vienna, Austria — September 8, 2026 TAmiRNA is proud to announce that it has joined six other independent European RNA companies — Anemocyte, Genevia Technologies, Immagina Biotechnology, Lexogen, MultiplexDX, and siTOOLS Biotech — as a founding member of the European RNA Alliance (ERA), a new strategic alliance launched today to strengthen Europe's position in high-quality RNA technologies. RNA technologies are increasingly central to modern medicine — diagnostics, disease monitoring, prophylaxis, therapeutics, and personalized treatment. Yet Europe's considerable expertise in this space is [...]

1 09, 2026

TAmiRNA is a Silver Sponsor at the D-A-CH EV Meeting 2026 in Erlangen

2026-09-01T10:20:37+02:00September 1st, 2026|biomarker, circulating miRNAs, Conference, EV characterization, exosomes, extracellular vesicle, microRNA services, miND, miND spike ins, RNA, small RNA-sequencing, smallRNA|Comments Off on TAmiRNA is a Silver Sponsor at the D-A-CH EV Meeting 2026 in Erlangen

From September 28–30, 2026, the D-A-CH EV Meeting 2026 will take place at the Hörsaalzentrum of the Medical Faculty, University Hospital Erlangen — the first joint annual meeting of the German, Austrian and Swiss societies for extracellular vesicles (GSEV, ASEV and SwissEV). Under the motto "Extracellular Vesicles: Communication Across Barriers," around 300 to 350 international scientists from the EV field will gather in Erlangen. The three-day programme covers the full breadth of EV research: from the fundamentals of EV biology, purification and characterization, to methodological advances, microbial EVs, clinical translation, reproducibility and open questions in EV research, as well as novel EV sources and emerging concepts. Keynote lectures, selected abstracts, poster sessions, roundtable discussions and industry presentations [...]

27 08, 2026

TAmiRNA at the 5th MC/WG Meeting of COST Action AtheroNET in Prague

2026-08-27T09:15:39+02:00August 27th, 2026|biomarker, Conference, RNA, small RNA-sequencing, smallRNA|Comments Off on TAmiRNA at the 5th MC/WG Meeting of COST Action AtheroNET in Prague

From September 2–4, 2026, the COST Action AtheroNET (CA21153) network will gather for its 5th Management Committee and Working Group meeting at the University of Chemical Technology in Prague. AtheroNET is supported by COST (European Cooperation in Science and Technology) and connects European research groups working on new approaches to understanding and diagnosing atherosclerosis. The three-day programme promises intensive scientific exchange: from a keynote lecture on B cells and humoral immunity as modulators of residual cardiovascular risk, through sessions from all four Working Groups (cardioprotection and immune mechanisms, omics-based risk stratification, standardisation and ring trials, and AI/multi-omics methods), to two Young Researchers & Innovators sessions and a poster session. We are especially pleased that Dr. Matthias Hackl, [...]

31 07, 2026

TAmiRNA CEO Dr. Matthias Hackl to Lecture on microRNA Biomarker Development at Jyväskylä Summer School 2026

2026-08-27T09:09:04+02:00July 31st, 2026|biomarker, circulating miRNAs, Conference, microRNA, microRNA services, miND, miND spike ins, miND spike-in, NGS, RNA, small RNA-sequencing, smallRNA|Comments Off on TAmiRNA CEO Dr. Matthias Hackl to Lecture on microRNA Biomarker Development at Jyväskylä Summer School 2026

Our CEO Dr. Matthias Hackl, a leading expert in microRNA biomarker discovery, small RNA sequencing, and IVD development, has been invited as a lecturer at this year's Jyväskylä Summer School at the University of Jyväskylä, Finland. As part of the course BIO1: MicroRNA Biology and Function (4–6 August 2026), he will join an international team of experts from Helsinki, Kuopio, and Jyväskylä to deliver a lecture on microRNA biomarker discovery, validation, and clinical application, titled: "microRNAs as Biomarkers: Discovery, Validation, and the Path to Clinical Application" Participants will: Understand what constitutes a clinically useful biomarker and how signal-to-noise ratio and pre-analytical, analytical, and biological variability impact biomarker study design Learn how small RNA sequencing (next-generation sequencing, NGS) [...]

3 06, 2026

Why Spike-ins Are the Key to Reproducible Small RNA-seq Data

2026-06-03T10:23:09+02:00June 3rd, 2026|microRNA, microRNA services, microRNAs, miND, miND spike ins, miND spike-in, NGS, small RNA-sequencing, smallRNA|Comments Off on Why Spike-ins Are the Key to Reproducible Small RNA-seq Data

Reproducibility is one of the biggest challenges in small RNA sequencing – and at the same time one of the most critical requirements for valid biomarker studies. Whether you are comparing data across batches, running multi-laboratory studies, or working with disease cohorts that show shifts in global RNA content: without an external reference, there is no reliable anchor to make your data truly comparable. This is exactly where TAmiRNA's miND® Spike-ins come in. In our new miND® Spike-ins FAQ Guide, we answer the three most frequently asked questions we receive from researchers and CRO partners. How are spike-ins used? miND® Spike-ins are added directly to extracted RNA immediately before library preparation. This means they travel through the [...]

14 10, 2025

hepatoMX Project Kickoff: TAmiRNA and You2Yourself Join Forces to Develop a Groundbreaking Urinary microRNA Diagnostic for Liver Disease

2025-10-14T08:25:31+02:00October 14th, 2025|biomarker, Biomarker Discovery, biomarkers, hepatoMX, Illumina NewSeq2000, microRNA services, microRNAs, miND, miND spike ins, NGS, sequencing, small RNA-sequencing, smallRNA|Comments Off on hepatoMX Project Kickoff: TAmiRNA and You2Yourself Join Forces to Develop a Groundbreaking Urinary microRNA Diagnostic for Liver Disease

We are excited to announce the official start of the EUREKA Eurostars project hepatoMX — a three-year collaboration between You2Yourself (Y2Y), a Dutch company specializing in small RNA-based early disease detection, and TAmiRNA GmbH, an Austrian SME with expertise in microRNA biomarker discovery and diagnostic test development (hepatomiR®). The project officially started on April 1, 2025, and aims to revolutionize the early detection of metabolic liver disease. The hepatoMX project will leverage TAmiRNA’s clinical expertise in liver diagnostics and Y2Y’s unique Urimon cohort that captures the dynamics of disease development to deliver a validated diagnostic test utilizing a proprietary urinary microRNA biomarker panel to identify early-stage liver disease in a simple and non-invasive manner. This innovative approach [...]

9 10, 2025

Microvascular microRNA Signatures in Sepsis: A High-Resolution View

2025-10-09T10:29:18+02:00October 9th, 2025|biomarker, Biomarker Discovery, biomarkers, Illumina NewSeq2000, laser microdissection (LMD), microRNA services, microRNAs, miND, miND spike ins, NGS, sequencing, small RNA-sequencing, smallRNA|Comments Off on Microvascular microRNA Signatures in Sepsis: A High-Resolution View

Sepsis drives profound microvascular injury, particularly in the kidney. But how do microRNAs (miRNAs) - the small regulators of gene expression - respond within distinct vascular compartments during this insult? A new study by Luxen et al.  published in Scientific Reports on October 2nd 2025 takes on this question using a clever methodological combination: laser microdissection (LMD) of microvascular subregions (arterioles, glomeruli, capillaries, postcapillary venules) followed by small RNA sequencing using TAmiRNA´s miND® workflow for highly sensitive and quantitative microRNA analysis. Why this approach matters Traditional microRNA profiling of whole tissues obscures spatial heterogeneity. With LMD, the authors could precisely isolate defined microvascular zones from kidney sections. Even with the tiny RNA yields from these isolated compartments, [...]

27 03, 2025

EVscale™ and TAmiRNA at ISEV Vienna, April 24-27, 2025

2025-03-27T10:53:51+01:00March 27th, 2025|biomarker, biomarkers, Evercyte, EVscale, extracellular vesicle, microRNAs, Personalized medicine, smallRNA|Comments Off on EVscale™ and TAmiRNA at ISEV Vienna, April 24-27, 2025

We are thrilled to announce that TAmiRNA, Evercyte, and Phoenestra have united to form EVscale™, a powerful collaboration dedicated to providing comprehensive solutions for extracellular vesicle (EV) research, diagnostic, and therapeutic development. We will be exhibiting at the prestigious ISEV (International Society for Extracellular Vesicles) Conference in Vienna from April 24-27, 2025, and we invite you to visit us at Booth B13. The EV Scale platform is designed to streamline every step of your EV workflow, catering to both therapeutic development and sophisticated omics-based biomarker discovery. Leveraging the unique expertise of each partner, we offer an integrated approach that encompasses: Optimized EV Production for Therapeutics: Utilizing a range of high-quality mesenchymal stromal cell (MSC) lines from Evercyte, [...]

20 02, 2025

TAmiRNA and Medical University of Vienna Advance Liver Surgery Safety with hepatomiR®

2025-02-20T08:56:56+01:00February 20th, 2025|biomarker, biomarkers, CE-IVD, hepatomiR kit, Liver disease, microRNAs, MUW, Personalized medicine, smallRNA|Comments Off on TAmiRNA and Medical University of Vienna Advance Liver Surgery Safety with hepatomiR®

TAmiRNA has joined forces with the Medical University of Vienna to develop an innovative microRNA test (hepatomiR®) to improve safety in liver surgery. The pioneering qPCR-based test is founded on original research by two of the university’s associate professors, Dr. Alice Assinger, Head of the Vienna Platelet Lab, and Dr. Patrick Starlinger, who heads the university’s TELL Translational and Experimental Liver Laboratory. Their work on the mechanisms of circulating microRNAs complements original work done by TAmiRNA over the past decade. Urgent medical need This work has resulted in an easy-to-use CE-IVD-certified qPCR test for standardized determination of hepatocyte- and endothelial-derived microRNAs. The individual miRNA levels are converted into a liver function score (P-Score) to ascertain a patient´s [...]

Go to Top